Benefiting from the gradual lifting of confinement measures, Ipsen reported a robust sales acceleration in Q2 with the neurosciences and oncology franchisees leading the gains. The margin advanced considerably, led by operational leverage and strict cost management. Importantly, FY21 sales and profitability targets have been raised, assuming a progressive recovery from the pandemic. Although the upcoming generic erosion of Somatuline continues to be a risk, new drug approvals and the recently-st ....
29 Jul 2021
Neurosciences and oncology ensure a strong beat in Q2; FY21 outlook raised
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Neurosciences and oncology ensure a strong beat in Q2; FY21 outlook raised
Benefiting from the gradual lifting of confinement measures, Ipsen reported a robust sales acceleration in Q2 with the neurosciences and oncology franchisees leading the gains. The margin advanced considerably, led by operational leverage and strict cost management. Importantly, FY21 sales and profitability targets have been raised, assuming a progressive recovery from the pandemic. Although the upcoming generic erosion of Somatuline continues to be a risk, new drug approvals and the recently-st ....